Drugs / BPI-572270
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07435038 | Feb 2026 → Dec 2028 expected | colorectal cancer, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Betta Pharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-04-30 | Betta Pharmaceuticals Co., Ltd. | Results 贝达药业四项研究成果亮相2025AACR年会 bettapharma.com ↗
BPI-572270在KRAS G12V 和KRAS G12D 的人胰腺癌异种移植小鼠模型中，低剂量每天口服给药一次可实现肿瘤消退。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-04-30 | Betta Pharmaceuticals Co., Ltd. | 贝达药业四项研究成果亮相2025AACR年会 bettapharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BPI-572270 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07435038 ↗ |
| Route | Oral | “Oral Tablets” NCT07435038 ↗ |